News
NewYorkBio Appoints 2026 Board of Directors
Overview
NewYorkBIO appointed the 2026 Board of Directors representing various sectors and share a commitment to advancing the growth of New York’s statewide life science industry.
The new class of leaders includes Andrew Lam of Ally Bridge Group,Theresa Mazzullo of Excell Partners, Monica Shaw of Bristol Myers Squibb and Julia Nanyi Zhao, PhD of BioLabs@NYU.
The following board members were reelected to serve another three-year term: Rana Al-Hallaq llaq of Pfizer Ventures, Matt Badalucco of Merck, Dawn Bell of Kardigan.Bio, Lis Leiderman, MD,
Robert Van Nostrand a Veteran Biotech CFO, Manan Shah of 1619 Advisors and Alan Tamarelli of Cooley LLP.
The Big Picture
Each year, the Board of Directors are elected by the NewYorkBIO membership in recognition of their leadership in the life science community. Through their various roles, the Board aims to guide NewYorkBIO on their mission to strengthen the life sciences industry statewide and influence policy at a pivotal time of increased investment in healthcare research and innovation. The board also oversees NewYorkBIO’s efforts to convene and support bioscience companies, universities, research institutions, and other organizations that are committed to improving health outcomes throughout New York and worldwide.
